2026 Q1 -tulosraportti
97 päivää sitten
‧46 min
1,55 DKK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 5.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 1.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sittenIt will at some point be a fantastic day when all those who have shorted the stock get a beating - I look forward to this day.
·10 t sittenGN Store Nord: Demant's report makes me more positive before GN's Q2 📈 Demant's new Q2/H1 report I actually find very interesting for GN. Demant delivered 10 % organic growth in external Hearing Aids sales in Q2, while the global hearing aid market, according to Demant, only grew by about 3 % in volume. At the same time, Demant raised its full-year organic growth expectation from 3-6% to 6-7% and EBIT guidance from DKK 4.1-4.5 bn to DKK 4.4-4.8 bn. This tells me first and foremost that the hearing aid market looks healthier than feared, and that innovation and new premium products can continue to create significant market share gains. This becomes very interesting for GN, because GN Hearing already delivered 9% organic growth in Q1. My expectation before GN's next report is therefore that Hearing can again deliver a strong quarter. A level around 7-9 % organic growth in Q2 will, in my assessment, be realistic, but that is my own estimate AND not GN's guidance. It is also positive for the value of the agreed DKK 17 bn transaction with Amplifon. GN is selling Hearing at a time when the industry is showing growth, product innovation, and opportunities for market share gains. But the biggest wildcard for the GN share will be Enterprise. If GN can combine: - 7-9 % Hearing growth - stabilization in Enterprise after -5 % in Q1 - better Gaming growth - maintained guidance - Amplifon transaction still on track ...then I think we have a fundamentally much stronger setup than the share price around DKK 100 immediately signals. And then the short positioning comes on top. Short interest, according to the latest data we have seen, has fallen from about 11.43% to 9.67%. That is still very high, but the direction is interesting. I am not building the GN case on a short squeeze. It must be the report, improved operations, and the value realization from Hearing that drives the share. But if GN delivers, while short positions continue to fall, it can naturally amplify the share price reaction. Demant's report is not proof that GN will deliver a strong Q2. Demant itself is gaining market share, and that must be respected. But as an industry read-through, I clearly think yesterday's report is positive for GN. Now GN itself must deliver. If Enterprise starts to turn around simultaneously with continued strong Hearing, DKK 100 could, in my assessment, become a much more interesting level than the market currently suggests. 🚀 Good luck to all GN shareholders.
·23 t sittenWill Demant's upward adjustment rub off on GN?
I myself own GN and it's probably the worst decision ever, apart from not buying a Hornsleth painting back when the artist was totally unknown. Immediately, GN is screwing everything up, in my opinion they have a board that is not suitable, but now we're talking "contagion" one can hope for that. Personally set 25% loss as the red button and then we take the loss and rip off the band-aid. GN has been a pure disaster- ·1 päivä sittenGN Store Nord: The shorts are letting go a bit, but DKK 100 is still the battlefield In my opinion, GN has become technically very interesting around DKK 100. Short interest has fallen significantly from around 11.43% to 9.67%. This corresponds to a drop of 1.76 percentage points or approx. 15% of the previous short position. This is therefore not insignificant short-covering. Nevertheless, a full 9.67% remains short, and Zirium also shows 33.8 days-to-cover. This is a very significant positioning in the stock. The interesting thing is the price development: GN is trading around DKK 99.32, and we have repeatedly seen attempts to get above DKK 100, after which the stock is pushed back. In my assessment, this looks like a real battle between buyers and sellers around the psychologically important 100-level. However, I will not conclude that the shorts are manipulating or actively "holding" GN below DKK 100. Price data alone cannot prove this. But with almost 10% short, it is difficult to ignore that the short positioning can be a significant part of the supply side in the stock. At the same time, it is worth remembering that GN's next big fundamental test comes already on August 20 with the Q2 report. N reported in Q1 continued challenges in Enterprise in EMEA, but stronger development in North America/APAC and good progress for Evolve3. And then there's the elephant in the room: the sale of GN Hearing to Amplifon for EUR 2.3 billion, where GN is to receive EUR 1.69 billion cash plus 56 million Amplifon shares, corresponding to approx. 16% of the combined company. My point: The shorts still have a very large position in GN, but short interest is actually moving in the right direction for long investors. If GN convincingly breaks DKK 100 and Q2 delivers, the question suddenly becomes not only whether the shorts can maintain the pressure, but how many will want to reduce further. 9.67% short is still a lot. But the drop from 11.43% is, in my opinion, at least as interesting as the level itself.
They are getting out too cheaply, the shorts, but that's up to the sellers themselves.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
97 päivää sitten
‧46 min
1,55 DKK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenIt will at some point be a fantastic day when all those who have shorted the stock get a beating - I look forward to this day.
- ·10 t sittenGN Store Nord: Demant's report makes me more positive before GN's Q2 📈 Demant's new Q2/H1 report I actually find very interesting for GN. Demant delivered 10 % organic growth in external Hearing Aids sales in Q2, while the global hearing aid market, according to Demant, only grew by about 3 % in volume. At the same time, Demant raised its full-year organic growth expectation from 3-6% to 6-7% and EBIT guidance from DKK 4.1-4.5 bn to DKK 4.4-4.8 bn. This tells me first and foremost that the hearing aid market looks healthier than feared, and that innovation and new premium products can continue to create significant market share gains. This becomes very interesting for GN, because GN Hearing already delivered 9% organic growth in Q1. My expectation before GN's next report is therefore that Hearing can again deliver a strong quarter. A level around 7-9 % organic growth in Q2 will, in my assessment, be realistic, but that is my own estimate AND not GN's guidance. It is also positive for the value of the agreed DKK 17 bn transaction with Amplifon. GN is selling Hearing at a time when the industry is showing growth, product innovation, and opportunities for market share gains. But the biggest wildcard for the GN share will be Enterprise. If GN can combine: - 7-9 % Hearing growth - stabilization in Enterprise after -5 % in Q1 - better Gaming growth - maintained guidance - Amplifon transaction still on track ...then I think we have a fundamentally much stronger setup than the share price around DKK 100 immediately signals. And then the short positioning comes on top. Short interest, according to the latest data we have seen, has fallen from about 11.43% to 9.67%. That is still very high, but the direction is interesting. I am not building the GN case on a short squeeze. It must be the report, improved operations, and the value realization from Hearing that drives the share. But if GN delivers, while short positions continue to fall, it can naturally amplify the share price reaction. Demant's report is not proof that GN will deliver a strong Q2. Demant itself is gaining market share, and that must be respected. But as an industry read-through, I clearly think yesterday's report is positive for GN. Now GN itself must deliver. If Enterprise starts to turn around simultaneously with continued strong Hearing, DKK 100 could, in my assessment, become a much more interesting level than the market currently suggests. 🚀 Good luck to all GN shareholders.
- ·23 t sittenWill Demant's upward adjustment rub off on GN?I myself own GN and it's probably the worst decision ever, apart from not buying a Hornsleth painting back when the artist was totally unknown. Immediately, GN is screwing everything up, in my opinion they have a board that is not suitable, but now we're talking "contagion" one can hope for that. Personally set 25% loss as the red button and then we take the loss and rip off the band-aid. GN has been a pure disaster
- ·1 päivä sittenGN Store Nord: The shorts are letting go a bit, but DKK 100 is still the battlefield In my opinion, GN has become technically very interesting around DKK 100. Short interest has fallen significantly from around 11.43% to 9.67%. This corresponds to a drop of 1.76 percentage points or approx. 15% of the previous short position. This is therefore not insignificant short-covering. Nevertheless, a full 9.67% remains short, and Zirium also shows 33.8 days-to-cover. This is a very significant positioning in the stock. The interesting thing is the price development: GN is trading around DKK 99.32, and we have repeatedly seen attempts to get above DKK 100, after which the stock is pushed back. In my assessment, this looks like a real battle between buyers and sellers around the psychologically important 100-level. However, I will not conclude that the shorts are manipulating or actively "holding" GN below DKK 100. Price data alone cannot prove this. But with almost 10% short, it is difficult to ignore that the short positioning can be a significant part of the supply side in the stock. At the same time, it is worth remembering that GN's next big fundamental test comes already on August 20 with the Q2 report. N reported in Q1 continued challenges in Enterprise in EMEA, but stronger development in North America/APAC and good progress for Evolve3. And then there's the elephant in the room: the sale of GN Hearing to Amplifon for EUR 2.3 billion, where GN is to receive EUR 1.69 billion cash plus 56 million Amplifon shares, corresponding to approx. 16% of the combined company. My point: The shorts still have a very large position in GN, but short interest is actually moving in the right direction for long investors. If GN convincingly breaks DKK 100 and Q2 delivers, the question suddenly becomes not only whether the shorts can maintain the pressure, but how many will want to reduce further. 9.67% short is still a lot. But the drop from 11.43% is, in my opinion, at least as interesting as the level itself.They are getting out too cheaply, the shorts, but that's up to the sellers themselves.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 5.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 1.5.2025 |
2026 Q1 -tulosraportti
97 päivää sitten
‧46 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 5.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 1.5.2025 |
1,55 DKK/osake
Viimeisin osinko
0,00%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenIt will at some point be a fantastic day when all those who have shorted the stock get a beating - I look forward to this day.
- ·10 t sittenGN Store Nord: Demant's report makes me more positive before GN's Q2 📈 Demant's new Q2/H1 report I actually find very interesting for GN. Demant delivered 10 % organic growth in external Hearing Aids sales in Q2, while the global hearing aid market, according to Demant, only grew by about 3 % in volume. At the same time, Demant raised its full-year organic growth expectation from 3-6% to 6-7% and EBIT guidance from DKK 4.1-4.5 bn to DKK 4.4-4.8 bn. This tells me first and foremost that the hearing aid market looks healthier than feared, and that innovation and new premium products can continue to create significant market share gains. This becomes very interesting for GN, because GN Hearing already delivered 9% organic growth in Q1. My expectation before GN's next report is therefore that Hearing can again deliver a strong quarter. A level around 7-9 % organic growth in Q2 will, in my assessment, be realistic, but that is my own estimate AND not GN's guidance. It is also positive for the value of the agreed DKK 17 bn transaction with Amplifon. GN is selling Hearing at a time when the industry is showing growth, product innovation, and opportunities for market share gains. But the biggest wildcard for the GN share will be Enterprise. If GN can combine: - 7-9 % Hearing growth - stabilization in Enterprise after -5 % in Q1 - better Gaming growth - maintained guidance - Amplifon transaction still on track ...then I think we have a fundamentally much stronger setup than the share price around DKK 100 immediately signals. And then the short positioning comes on top. Short interest, according to the latest data we have seen, has fallen from about 11.43% to 9.67%. That is still very high, but the direction is interesting. I am not building the GN case on a short squeeze. It must be the report, improved operations, and the value realization from Hearing that drives the share. But if GN delivers, while short positions continue to fall, it can naturally amplify the share price reaction. Demant's report is not proof that GN will deliver a strong Q2. Demant itself is gaining market share, and that must be respected. But as an industry read-through, I clearly think yesterday's report is positive for GN. Now GN itself must deliver. If Enterprise starts to turn around simultaneously with continued strong Hearing, DKK 100 could, in my assessment, become a much more interesting level than the market currently suggests. 🚀 Good luck to all GN shareholders.
- ·23 t sittenWill Demant's upward adjustment rub off on GN?I myself own GN and it's probably the worst decision ever, apart from not buying a Hornsleth painting back when the artist was totally unknown. Immediately, GN is screwing everything up, in my opinion they have a board that is not suitable, but now we're talking "contagion" one can hope for that. Personally set 25% loss as the red button and then we take the loss and rip off the band-aid. GN has been a pure disaster
- ·1 päivä sittenGN Store Nord: The shorts are letting go a bit, but DKK 100 is still the battlefield In my opinion, GN has become technically very interesting around DKK 100. Short interest has fallen significantly from around 11.43% to 9.67%. This corresponds to a drop of 1.76 percentage points or approx. 15% of the previous short position. This is therefore not insignificant short-covering. Nevertheless, a full 9.67% remains short, and Zirium also shows 33.8 days-to-cover. This is a very significant positioning in the stock. The interesting thing is the price development: GN is trading around DKK 99.32, and we have repeatedly seen attempts to get above DKK 100, after which the stock is pushed back. In my assessment, this looks like a real battle between buyers and sellers around the psychologically important 100-level. However, I will not conclude that the shorts are manipulating or actively "holding" GN below DKK 100. Price data alone cannot prove this. But with almost 10% short, it is difficult to ignore that the short positioning can be a significant part of the supply side in the stock. At the same time, it is worth remembering that GN's next big fundamental test comes already on August 20 with the Q2 report. N reported in Q1 continued challenges in Enterprise in EMEA, but stronger development in North America/APAC and good progress for Evolve3. And then there's the elephant in the room: the sale of GN Hearing to Amplifon for EUR 2.3 billion, where GN is to receive EUR 1.69 billion cash plus 56 million Amplifon shares, corresponding to approx. 16% of the combined company. My point: The shorts still have a very large position in GN, but short interest is actually moving in the right direction for long investors. If GN convincingly breaks DKK 100 and Q2 delivers, the question suddenly becomes not only whether the shorts can maintain the pressure, but how many will want to reduce further. 9.67% short is still a lot. But the drop from 11.43% is, in my opinion, at least as interesting as the level itself.They are getting out too cheaply, the shorts, but that's up to the sellers themselves.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt